BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineOBGYN & Women's HealthHematology & OncologyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerGeneral HealthSurgery
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, April 2, 2019 (HealthDay News) -- For patients with human epidermal growth factor receptor 2-positive (HER2+) stage IV breast cancer, surgery is associated with improved survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 29 to April 3 in Atlanta.
Ross Mudgway, from the University of California Riverside School of Medicine, and colleagues examined the impact of primary tumor resection on survival in 3,231 women with HER2+ stage IV breast cancer.
The researchers found that 35.0 and 65.0 percent of patients underwent primary site surgery and did not have surgery, respectively. The odds of having surgery were increased for those with Medicare/other government or private insurance versus no insurance/Medicaid (odds ratios, 1.36 and 1.93, respectively), as well as for patients receiving radiation (odds ratio, 2.10), chemotherapy/immunotherapy (odds ratio, 1.99), and endocrine therapy (odds ratio, 1.73). The likelihood of having surgery was lower for non-Hispanic black versus non-Hispanic white patients (odds ratio, 0.68) and those treated in academic/research versus community programs (odds ratio, 0.67). Lower mortality hazard ratios were seen in association with insurance, receipt of chemotherapy/immunotherapy, and receipt of endocrine therapy (hazard ratios, 0.36, 0.76, and 0.70, respectively). Surgery was associated with improved survival versus no surgery in propensity score analysis (hazard ratio, 0.56).
"In addition to standard HER2 targeted medications and other adjuvant therapy, if a woman has stage 4 HER2+ breast cancer, surgery to remove the primary breast tumor should be considered," a coauthor said in a statement.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 27, 2022
Read this Next
Other Trending Articles